Category: Mergers and Acquisitions

June 9, 2021

The treatment, being developed by Merck in collaboration with Ridgeback Biotherapeutics, is currently being evaluated in a phase 3 clinical trial. The trial, know as the MOVe-OUT study, is evaluating molnupiravir in the treatment of non-hospitalised patients with laboratory-confirmed COVID-19 […]

June 3, 2021

Venture capitalists interested in biotech have been able to raise money with unprecedented ease over the past several years. Polaris Partners, 5AM Ventures, Third Rock Ventures, Versant and venBio are just some of the firms to have secured hundreds of […]

June 1, 2021

HS-001, Heartseed’s lead asset, is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). The therapy is currently being developed as a treatment for heart failure. Heartseed is already planning to launch a phase 1/2 […]

May 6, 2021

According to Paul Matteis, an analyst at Stifel, the closing of the deal removes a question mark hanging over UniQure’s stock. Regulators, especially those in the U.S., are taking harder looks at pharmaceutical acquisitions, suggesting that approval of the UniQure-CSL […]

May 6, 2021

Two biotechs aim to broaden the reach of cancer immunotherapy by applying gene editing tools to an emerging form of cell therapy through a wide-ranging collaboration. The agreement, between CRISPR Therapeutics and Nkarta, includes three components. The biotechs will first […]

April 29, 2021

Pfizer has acquired Amplyx Pharmaceuticals, a privately-held company dedicated to the development of therapies for immune system disorders. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. Financial terms were […]

April 27, 2021

Samsung Biologics announced on April 26, 2021 that it has expanded its 2018 contract manufacturing deal with TG Therapeutics, a US based healthcare company, for the supply of TG’s ublituximab, an investigational anti-CD20 monoclonal antibody (mAb). Since the start of […]

April 22, 2021

Cell therapy is a treatment involving the genetic modification and reprogramming of a patient’s immune cells to target their own specific cancer, making it a truly individualised medicine. It’s one of the most promising – and one of the most […]

April 21, 2021

Following the amended agreement, Vertex will now lead the global development, manufacturing and commercialisation of the gene therapy CTX001, with support from CRISPR Therapeutics. In December, Vertex and CRISPR Therapeutics announced new, early-stage data from a total of ten patients […]

April 20, 2021

GAMUT’s lead product, now SPVN20, is a novel, mutation-agnostic gene therapy, which aims at restoring the function of dormant cone cells in the retina. If approved it would compete with Novartis’ Luxturna (voretigene neparvovec), the gene therapy from Roche/Spark Therapeutics, […]

March 23, 2021

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa” or the “Company”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously […]

February 9, 2021

Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the expansion of its T cell engineered therapy […]